{"id":"NCT01178125","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy","officialTitle":"A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-102) for the Prevention of Pregnancy in Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2013-01","completion":"2013-01","firstPosted":"2010-08-09","resultsPosted":"2013-12-11","lastUpdate":"2021-11-09"},"enrollment":2858,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Contraception","Female Contraception"],"interventions":[{"type":"DRUG","name":"DR-102","otherNames":[]}],"arms":[{"label":"DR-102","type":"EXPERIMENTAL"}],"summary":"This is an open-label, single treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-102. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a daily diary.","primaryOutcome":{"measure":"All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day Rule","timeFrame":"thirteen 28-day cycles","effectByArm":[{"arm":"DR-102: Total","deltaMin":2.43,"sd":null},{"arm":"DR-102: Baseline Body Weight <90 kg","deltaMin":2.35,"sd":null},{"arm":"DR-102: Baseline Body Weight â‰¥90 kg","deltaMin":2.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":62,"countries":["United States","Israel"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":2765},"commonTop":["Nasopharyngitis","Upper respiratory infection","Sinusitus","Headache","Nausea"]}}